Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Immunogenomic Landscape Contributes to Hyperprogressive Disease after Anti-PD-1 Immunotherapy for Cancer
Donghai Xiong, Yian Wang, Arun K. Singavi, et al.
iScience (2018) Vol. 9, pp. 258-277
Open Access | Times Cited: 91

Showing 1-25 of 91 citing articles:

Recent progress of chemodynamic therapy-induced combination cancer therapy
Xianwen Wang, Xianyan Zhong, Zhuang Liu, et al.
Nano Today (2020) Vol. 35, pp. 100946-100946
Closed Access | Times Cited: 568
Newly developed strategies for improving sonodynamic therapy
Xianwen Wang, Xiaoyan Zhong, Fei Gong, et al.
Materials Horizons (2020) Vol. 7, Iss. 8, pp. 2028-2046
Closed Access | Times Cited: 224
Exploring immunotherapy in colorectal cancer
Junyong Weng, Shanbao Li, Zhonglin Zhu, et al.
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 222
The cutting-edge progress of immune-checkpoint blockade in lung cancer
Fei Zhou, Meng Qiao, Caicun Zhou
Cellular and Molecular Immunology (2020) Vol. 18, Iss. 2, pp. 279-293
Open Access | Times Cited: 158
NLRP3 inflammasome-mediated cytokine production and pyroptosis cell death in breast cancer
Sara Socorro Faria, Susan Costantini, Vladmir Cláudio Cordeiro de Lima, et al.
Journal of Biomedical Science (2021) Vol. 28, Iss. 1
Open Access | Times Cited: 124
Reshaping the systemic tumor immune environment (STIE) and tumor immune microenvironment (TIME) to enhance immunotherapy efficacy in solid tumors
Liangliang Xu, Chang Zou, Shanshan Zhang, et al.
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 115
Hyperprogression and Immunotherapy: Fact, Fiction, or Alternative Fact?
Jacob J. Adashek, Ishwaria M. Subbiah, Ignacio Matos, et al.
Trends in cancer (2020) Vol. 6, Iss. 3, pp. 181-191
Open Access | Times Cited: 107
Harnessing the immune system against cancer: current immunotherapy approaches and therapeutic targets
Ayana R. Kumar, Aswathy R. Devan, Bhagyalakshmi Nair, et al.
Molecular Biology Reports (2021) Vol. 48, Iss. 12, pp. 8075-8095
Open Access | Times Cited: 92
Cancer stem cells in immunoregulation and bypassing anti-checkpoint therapy
Elnaz Rouzbahani, Jamal Majidpoor, Sajad Najafi, et al.
Biomedicine & Pharmacotherapy (2022) Vol. 156, pp. 113906-113906
Open Access | Times Cited: 46
Divergent functions of NLRP3 inflammasomes in cancer: a review
Alireza Shadab, Mohamad Mahjoor, Mohammad Abbasi‐Kolli, et al.
Cell Communication and Signaling (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 36
Fcγ receptors and immunomodulatory antibodies in cancer
Felipe Gálvez‐Cancino, Alexander P. Simpson, Cristóbal Costoya, et al.
Nature reviews. Cancer (2023) Vol. 24, Iss. 1, pp. 51-71
Closed Access | Times Cited: 29
Predicting immunotherapy response of advanced bladder cancer through a meta-analysis of six independent cohorts
Lilian Marie Boll, Sergio Vázquez Montes de, Marta E. Camarena, et al.
Nature Communications (2025) Vol. 16, Iss. 1
Open Access | Times Cited: 1
How Can Immune Checkpoint Inhibitors Cause Hyperprogression in Solid Tumors?
Morgane Denis, M. Duruisseaux, Marie Brevet, et al.
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 53
NOTCH3 is a Prognostic Factor and Is Correlated With Immune Tolerance in Gastric Cancer
Yuehong Cui, Qian Li, Wei Li, et al.
Frontiers in Oncology (2021) Vol. 10
Open Access | Times Cited: 43
Prognostic and Predictive Biomarkers in the Era of Immunotherapy for Lung Cancer
L. Pabst, Sébastien Lopes, Basil Bertrand, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 8, pp. 7577-7577
Open Access | Times Cited: 20
Mechanisms of hyperprogressive disease after immune checkpoint inhibitor therapy: what we (don’t) know
Simone Camelliti, Valentino Le Noci, Francesca Bianchi, et al.
Journal of Experimental & Clinical Cancer Research (2020) Vol. 39, Iss. 1
Open Access | Times Cited: 50
EP300 knockdown reduces cancer stem cell phenotype, tumor growth and metastasis in triple negative breast cancer
Alexander Ring, Pushpinder Kaur, Julie E. Lang
BMC Cancer (2020) Vol. 20, Iss. 1
Open Access | Times Cited: 45
Pseudoprogression and hyperprogression in lung cancer: a comprehensive review of literature
Laiyan Zhou, Mai Zhang, Rui Li, et al.
Journal of Cancer Research and Clinical Oncology (2020) Vol. 146, Iss. 12, pp. 3269-3279
Closed Access | Times Cited: 40
Cancer cell-expressed BTNL2 facilitates tumour immune escape via engagement with IL-17A-producing γδ T cells
Yanyun Du, Qianwen Peng, Du Cheng, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 23
Targeting MDM2 in malignancies is a promising strategy for overcoming resistance to anticancer immunotherapy
Dantong Sun, Haili Qian, Junling Li, et al.
Journal of Biomedical Science (2024) Vol. 31, Iss. 1
Open Access | Times Cited: 5
Inhibition of NLRP3 inflammasome contributes to paclitaxel efficacy in triple negative breast cancer treatment
Liliana-Roxana Balahura, Sorina Dinescu
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 5
Bypassing anti-PD-(L)1 therapy: Mechanisms and management strategies
Keywan Mortezaee, Jamal Majidpoor, Sajad Najafi, et al.
Biomedicine & Pharmacotherapy (2022) Vol. 158, pp. 114150-114150
Open Access | Times Cited: 19
Helper-like innate lymphoid cells and cancer immunotherapy
Adeline Crinier, Éric Vivier, Mathieu Bléry
Seminars in Immunology (2019) Vol. 41, pp. 101274-101274
Open Access | Times Cited: 30
The implications of clinical risk factors, CAR index, and compositional changes of immune cells on hyperprogressive disease in non-small cell lung cancer patients receiving immunotherapy
Seoree Kim, Sang Hoon Chun, Joo Ri Kim, et al.
BMC Cancer (2021) Vol. 21, Iss. 1
Open Access | Times Cited: 26
Immunotherapy for the treatment of colorectal cancer
Melissa Lumish, Andrea Cercek
Journal of Surgical Oncology (2021) Vol. 123, Iss. 3, pp. 760-774
Closed Access | Times Cited: 26
Page 1 - Next Page

Scroll to top